CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting.
CorWave Presents an Unprecedented Chronic In Vivo Study at the 41st Annual Meeting of the International Society of Heart and Lung Transplantation.
CorWave Joins the French Tech 120 Index, a Community That Brings Together the Top French Tech Scale-up Companies.
CorWave Raises €35 Million in Series C Funding for Its Breakthrough Heart Pump; EIC Fund Joins as New Investor.
CorWave Secures a €500,000 Grant From the Paris Region for Its Industrial Facilities.
CorWave Awarded €2.5M From the European Commission Through the EIC Accelerator Program.
CorWave Reports Two Critical Technical Milestones Required to Proceed to the Clinical Phase at the American Society for Artificial Internal Organs Annual Meeting.
CorWave Appoints Jim Schuermann as an Independent Director.
CorWave Presented First Successful In Vivo 60-Day Study on Its Innovative LVAD Cardiac Support Device.
CorWave To Report First Successful In Vivo Survival at 30-Day Milestone with Its Innovative LVAD Cardiac Support Device.
CorWave’s next-generation LVAD receives funding.
Corwave Announces Issuance of US Patent Covering Its Implantable Left Ventricular Assist Device Leveraging the Wave Membrane Technology.
CorWave scales up increasing its R&D capabilities and opening a pilot production unit at its new Clichy site.
CorWave is pegged as a potential billion-euro company as part of “Future Unicorn” competition.
CorWave is set to receive about €3 million in financing through France’s Worldwide Innovation Challenge for its NovaPulse program, a mini-invasive solution for cardiac support.
CorWave Receives 2017 Deloitte ‘Technology Fast 50 Biotech of the Future’ Award of the Parisian Region.
CorWave Raises $17.1 Million in Series B Financing.
CorWave Awarded at the Worldwide Innovation Challenge.
CorWave Presents Promising Early Results for Innovative Wave Membrane Blood Pump.